Blog
RSS FeedPosted by Michael Wonder on 29 Aug 2018
Proposal to move to one funded brand of lamotrigine (Logem)
29 August 2018 - PHARMAC is seeking feedback on a proposed change to the funding of lamotrigine dispersible tablets used ...
Posted by Michael Wonder on 27 Aug 2018
Update on proposal to fund a pangenotypic hepatitis C treatment - glecaprevir and pibrentasvir (Maviret)
27 August 2018 - PHARMAC would like to thank everyone who provided feedback on a proposal to fund glecaprevir and ...
Posted by Michael Wonder on 21 Aug 2018
Proposal to change the funded brand of epoetin alfa
21 August 2018 - PHARMAC is seeking feedback on a proposed change to the funded brand of epoetin alfa [erythropoietin ...
Posted by Michael Wonder on 20 Aug 2018
Proposal to list nintedanib (Ofev) and remove restrictions from tiotropium bromide (Spiriva)
20 August 2018 - PHARMAC is seeking feedback on a proposal to list nintedanib (Ofev) and remove the current funding ...
Posted by Michael Wonder on 01 Aug 2018
Free access plan for 'revolutionary' drug that could eliminate Hepatitis C by 2030
1 August 2018 - What has been called a "revolutionary" hepatitis C drug could soon be available free-of-charge to all ...
Posted by Michael Wonder on 20 Jul 2018
Proposal to fund a pangenotypic hepatitis C treatment - glecaprevir and pibrentasvir (Maviret)
20 July 2018 - PHARMAC is seeking feedback on a proposal to fund a pangenotypic treatment for chronic hepatitis C ...
Posted by Michael Wonder on 02 Jul 2018
Another multi-product proposal from Novartis, this time involving ten pharmaceuticals
2 July 2018 - PHARMAC is seeking feedback on a proposal to fund five new treatments, widen access to three ...
Posted by Michael Wonder on 17 May 2018
Proposal to widen access and change the funded enzyme replacement therapy for Gaucher disease
17 May 2018 - PHARMAC is seeking feedback on proposed changes to the funding of enzyme replacement therapy used in ...
Posted by Michael Wonder on 09 Apr 2018
Proposal to remove the funding restrictions for candesartan
9 April 2018 - Following assessment of bids in PHARMAC’s 2017/18 annual Invitation to Tender, PHARMAC is proposing to remove ...
Posted by Michael Wonder on 05 Apr 2018
Proposal to list mercaptopurine oral suspension
5 April 2018 - PHARMAC is seeking feedback on a proposal to list mercaptopurine oral solution (Allmercap) 20 mg/mL from ...
Posted by Michael Wonder on 27 Mar 2018
Proposal to fund aflibercept and rivaroxaban
27 March 2018 - PHARMAC is seeking feedback on a proposal to list aflibercept (Eylea) and rivaroxaban (Xarelto) through a ...
Posted by Michael Wonder on 15 Mar 2018
Proposal to fund denosumab for osteoporosis
16 March 2018 - PHARMAC is proposing to fund denosumab (Prolia) injections from 1 June 2018 for the treatment of severe, ...
Posted by Michael Wonder on 15 Mar 2018
Decision to open list montelukast tablets
15 March 2018 - PHARMAC will remove the Special Authority and Hospital Medicine restrictions on montelukast 4 mg, 5 mg ...
Posted by Michael Wonder on 11 Mar 2018
Proposal to widen access and change the funded brand of tenofovir disoproxil and entecavir
9 March 2018 - PHARMAC is delighted to propose the widening of access to tenofovir disoproxil and entecavir, anti-viral medicines ...
Posted by Michael Wonder on 24 Jan 2018
Proposal to list eplerenone for the treatment of heart failure in patients intolerant to spironolactone
24 January 2018 - Following assessment of bids in PHARMAC’s 2017/18 annual Invitation to Tender, PHARMAC is proposing to fund ...